论文部分内容阅读
作者对急性缺血性年中发病3h内的治疗,采用随机、双盲、安慰剂对照试验,以检验静脉输入重组组织型纤维蛋白溶酶原激活剂(rt-PA)的治疗价值。 全组27例,按照发病到开始治疗的时间分为90min内和91～180min两组。在90min组的20例中,随机分为rt-PA组10例及对照组10例,在91～180min组的7例中,分为rt-PA组4例及对照组3例。病人接受rt-PA 0.85mg/kg或同量的安慰剂,在60min内连续静脉输入,总剂量的10％在治疗初一次注入。在治疗开始后0、30min、1h、2h,及卒中后24h、2天、7～10天和3月做出NIH卒中评分。在卒
The authors randomized, double-blind, placebo-controlled trials to assess the therapeutic value of intravenous recombinant tissue-type plasminogen activator (rt-PA) within 3 h of onset of acute ischemic midyear disease. The whole group of 27 cases, according to the onset of treatment time is divided into 90min and 91 ~ 180min two groups. In the 90 min group, 20 patients were randomly divided into rt-PA group and control group, 10 cases in the 91 ~ 180min group, 7 cases were divided into rt-PA group and control group. Patients received rt-PA 0.85mg / kg or the same amount of placebo, continuous intravenous infusion within 60min, the total dose of 10% at the beginning of treatment injection. NIH stroke scores were scored at 0, 30 min, 1 h, 2 h, 24 h, 2 days, 7-10 days and March after the start of treatment. In the pawn